Terns Pharmaceuticals, Inc. (TERN): Price and Financial Metrics
GET POWR RATINGS... FREE!
TERN Stock Price Chart Interactive Chart >
TERN Price/Volume Stats
| Current price | $2.40 | 52-week high | $13.77 |
| Prev. close | $2.28 | 52-week low | $1.45 |
| Day low | $2.19 | Volume | 96,200 |
| Day high | $2.48 | Avg. volume | 117,974 |
| 50-day MA | $1.84 | Dividend yield | N/A |
| 200-day MA | $5.33 | Market Cap | 60.67M |
Terns Pharmaceuticals, Inc. (TERN) Company Bio
Terns Pharmaceuticals, Inc. operates as a biopharmaceutical company. The Company discovers and develops molecularly-targeted and oral molecule drugs for the treatment of liver disease and cancer. Terns Pharmaceuticals serves customers worldwide.
Latest TERN News From Around the Web
Below are the latest news stories about Terns Pharmaceuticals Inc that investors may wish to consider to help them evaluate TERN as an investment opportunity.
Terns Pharmaceuticals, Inc. (NASDAQ:TERN): Are Analysts Optimistic?We feel now is a pretty good time to analyse Terns Pharmaceuticals, Inc.'s ( NASDAQ:TERN ) business as it appears the... |
Matthews International Capital Management Llc Buys Atlassian Corporation PLC, Pinduoduo Inc, ...San Francisco, CA, based Investment company Matthews International Capital Management Llc (Current Portfolio) buys Atlassian Corporation PLC, Pinduoduo Inc, Full Truck Alliance Co, TDCX Inc, Lam Research Corp, sells Sea, Bilibili Inc, XPeng Inc, MINISO Group Holding, Taiwan Semiconductor Manufacturing Co during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Matthews International Capital Management Llc. |
Terns Pharmaceuticals (TERN) Investor Presentation - slideshowNo summary available. |
Terns Pharmaceuticals Appoints Jeffrey R. Jasper, Ph.D., as Senior Vice President, Head of Research and Promotes Diana Chung to Senior Vice President, Chief Development OfficerFOSTER CITY, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases such as non-alcoholic steatohepatitis (NASH), today announced the appointment of Jeffrey R. Jasper, Ph.D., as senior vice president, head of research. Dr. Jasper joins Terns with more than 28 years of experience in |
Terns Pharmaceuticals to Present at 40th Annual J.P. Morgan Health Care ConferenceFOSTER CITY, Calif., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases such as non-alcoholic steatohepatitis (NASH), today announced that the Company’s management team will present at the following investor conferences in January: 40th Annual J.P. Morgan Health Care Conference Date: J |
TERN Price Returns
| 1-mo | N/A |
| 3-mo | -19.19% |
| 6-mo | -66.05% |
| 1-year | -80.69% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -66.05% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...